While we and others have shown the cancer inhibitory potential of C-PAC in multiple in vitro models (36), we believe the current study is the first to show that C-PAC inhibits reflux-driven EAC in vivo and to decipher mechanisms of inhibition linked to reflux-driven dysbiosis, transport, and metabolism of bile, and TLR/NF-κB/TP53 signaling. The gene discussed is TP53; the disease is cancer.